1. NeoGenomics will present at two major investor conferences. 2. The William Blair conference is on June 3, 1:00 pm ET. 3. The Jefferies conference will take place on June 4, 2:00 pm ET. 4. The company specializes in comprehensive oncology diagnostics and testing services. 5. Webcasts of the presentations will be available on their Investor Relations site.
Participating in recognized conferences can attract investor interest and enhance visibility. Previous conference participation has historically led to increased stock prices for similar biotech firms.
The conferences are key opportunities for NeoGenomics to showcase its innovations. Increased exposure can enhance investment confidence and influence short-term stock performance.
The immediate impact will be evident during and shortly after the conferences. Investor sentiment may shift quickly based on conference feedback and announcements.
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:
Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.